Results 91 to 100 of about 24,341 (292)

IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome

Journal of the American Society of Nephrology, 2021
Visual Abstract Significance Statement Atypical hemolytic uremic syndrome (aHUS) is often related to complement dysregulation, but its pathophysiology remains unknown in at list 30% of patients.
M. Cugno, S. Berra, Federica Depetri, S. Tedeschi, S. Griffini, E. Grovetti, S. Caccia, D. Cresseri, P. Messa, S. Testa, F. Giglio, F. Peyvandi, G. Ardissino   +12 more
semanticscholar   +1 more source

Immunosuppressive and Non‐Immunosuppressive Drugs for Heart Xenotransplantation in Humans: Is Europe Ready?

Xenotransplantation, Volume 32, Issue 4, July/August 2025.
ABSTRACT Xenotransplantation is becoming an emerging field of interest for the treatment of end‐stage heart disease. In fact, the shortage of human heart donors in European countries requires the increasing investigation of alternative strategies such as heart xenotransplantation.
Nicola Pradegan, Annamaria Tolomeo, Diego Ciccarelli, Emanuele Cozzi, Antonio Vitiello, Andrea Zovi, Gino Gerosa   +6 more
wiley   +1 more source

Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report

BMC Nephrology, 2019
Background Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury.
Subagini Nagarajah, Martin Tepel, Christian Nielsen, Kristian Assing, Yaseelan Palarasah, Lise Lotte Torvin Andersen, Lotte Borg Lange, Claus Bistrup   +7 more
doaj   +1 more source

Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005 [PDF]

, 2007
The prevalence, incidence and outcomes of haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopaenic purpura (TTP) are not well established in adults or children from prospective studies. We sought to identify both outcomes and current management
D. YOUNG, Hosler, K. G. J. POLLOCK, Marques, Sadler, T. J. BEATTIE, Tarr, Van Dyck, W. T. A. TODD   +8 more
core   +2 more sources

Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

Frontiers in Pharmacology, 2022
Hemolytic uremic syndrome (HUS) is a rare life-threatening disease of unrestrained complement system dysregulation, microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure in genetically predisposed individuals.
V. Leone, Amantia Imeraj, S. Gastoldi, C. Mele, L. Liguori, Carmelita Condemi, P. Ruggenenti, G. Remuzzi, Camillo Carrara   +8 more
semanticscholar   +1 more source

Acute Cerebrovascular Accident, Renal Failure, and Thrombotic Microangiopathy in a 27‐Year‐Old Male With Malignant Hypertension

Clinical Case Reports, Volume 13, Issue 6, June 2025.
ABSTRACT Hypertensive emergency is an acute, significant elevation of blood pressure accompanied by end‐organ damage. We present a case of a 27‐year‐old gentleman who acquired multiple complications of hypertensive emergency, including renal failure and microangiopathy.
Tatiana Gusan, Angelina Hong, Sarah Kaufman, Luis Santiago, Nathan Zaher   +4 more
wiley   +1 more source

Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso [PDF]

, 2016
Trobareu una actualització (2015) d'aquest document a: http://hdl.handle.net/2445/99427Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the ...
Arias, Manuel, Ariceta, Gema, Blasco, Miguel, Campistol Plana, Josep M., Espinosa, Mario, Grinyó Boira, Josep M., Praga, Manuel, Rodríguez de Córdoba, Santiago, Torra, Roser, Vilalta, Ramon (Vilalta Casas)   +9 more
core   +1 more source

Primary Thrombotic Microangiopathy in Pediatric Patients

Global Pediatric Health
Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology .
Andrés David Aranzazu Ceballos MD, Lina María Martínez Sánchez MSc, Ana Paulina Pamplona Sierra MD, Daniela Vergara Yánez MD, Liliana Franco Hincapié PhD, Richard Baquero Rodriguez MD   +5 more
doaj   +1 more source

When the environment and mutations affect organ systems [PDF]

, 2017
Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) with a genetic predisposition. Like other TMAs, it presents clinically with thrombocytopenia and microangiopathic hemolytic anemia, which is accompanied by disruption of
Abu Ghanimeh, Mouhanna, Abughanimeh, Omar, Qasem, Abdulraheem, Qasrawi, Ayman   +3 more
core   +1 more source

Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy

iMetaOmics, Volume 2, Issue 2, June 2025.
This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang   +7 more
wiley   +1 more source